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Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been
approved for the treatment of active multiple sclerosis, but expose to the onset of a rare
side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual
risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are
mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV)
seropositivity, treatment duration (with peak incidence after 24 months), and the previous
use of immunosuppressive therapies. Given that this stratification does not yet allow a
precise individual prediction of PML, other predictive markers are needed, and several
immunological biomarkers have been described. Quantification of anti-JCV antibody levels
may improve individual predictive value, with higher baseline titers indicating increased
risk. Other immunological biomarkers such as leukocyte cell membrane markers (CD49d,
CD11a, and CD62L), detection of circulating JCV-specific activatedT effector memory cells
(TEM) or genetic screening have been proposed. In this review, we discuss how recent
progress in immunology has paved the way for «new combined monitoring», which will
include immunological screening, in NTZ-treated patients.
Keywords: JC virus, multiple sclerosis, PML, risk stratification, selectin, effector memoryT-cells
INTRODUCTION
In 2006, natalizumab (NTZ, Tysabri®), a humanized monoclonal
antibody targeting the α chain of the α4β1 adhesion molecule, was
approved for the treatment of relapsing-remitting multiple sclero-
sis (RR-MS) (1). This approval was based on pivotal clinical trials
showing that NTZ decreased the mean annualized relapse rate by
68% and the risk of disability progression by 42% compared to
placebo (1).
This pivotal study not only demonstrated that NTZ therapy
could result in a quick benefit for RRMS patients, since the annu-
alized relapse rate was reduced [0.30 (95% CI 0.23–0.40) vs. 0.71
(95% CI 0.55–0.91) p< 0.0001] within the first 3 months, but
it also emphasized that the efficacy was even more pronounced
in patients with highly active disease [0.30 (95% CI 0.17–0.53)
vs. 0.94 (95% CI 0.55–1.63)]. Therefore, NTZ emerged as one of
the most powerful therapies for active relapsing MS, leading to
its rapid and widespread utilization in western countries. How-
ever, in contrast with the apparent favorable short-term safety,
chronic NTZ use has been associated with progressive multifocal
leukoencephalopathy (PML).
First described in 1958 by Astrom and Robertson, PML is a
life-threatening opportunistic viral encephalitis induced by JC
virus (JCV), and usually occurs in immunocompromised patients
(especially HIV+ patients) (2). The overall prevalence of PML
among NTZ-treated MS patients was first estimated at 1 case/1000
patients (3–6). However, additional cases have since occurred, and
492 PML cases were reported in 129,100 patients who received
at least 1 dose of NTZ up to September 2014. This has resulted
in a reviewed estimation of the overall incidence at 3.72/1000
patients (95% CI 3.4–4.06/1000 patients) (Biogen Idec data, Sep-
tember 2014, website http://www.biogenidec-international.com/
tysabri.aspx?).
The clinical presentation of NTZ-associated PML is not really
distinct from classical PML, and consists in cognitive disorders
in more than half of the patients together with motor symptoms,
ataxia, neurovisual disturbances, and dysphasia or agnosia in more
than 40% of cases (2, 7).
On MRI, lesions are generally large (more than 3 cm) and can
affect supratentorial and infratentorial white matter (2). These
lesions are usually hyperintense on T2 and FLAIR MRI sequences
and hypointense on T1 sequences. Diffusion weighted imaging
(DWI) can help in the diagnosis of PML in NTZ-treated patients
to differentiate active PML lesions from MS plaques. In con-
trast with non-NTZ-PML lesions, NTZ-associated PML lesions
frequently show gadolinium enhancement (43% of cases) (2, 8).
Since “asymptomatic NTZ-PML cases,” defined as subjects with a
possible PML lesion identified on MRI without any clinical PML
symptom, have been identified among patients who were mon-
itored by systematic MRIs, it is now recommended to perform
a regular MRI monitoring (every 3–6 months) among patients
at risk for PML, especially after 2 years of treatment (9, 10).
Indeed, MRI is very sensitive for the identification of PML recent
lesions that can be detected months before first clinical symptoms
(9, 10). Interestingly, contrasting with symptomatic PML where
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lesions tend to involve multiple lobes, «asymptomatic PML»cases
are characterized by a more localized disease with unilobar focal
lesion affecting predominantly the juxtacortical white matter and
the cortical gray matter of the frontal and parietal lobe (11).
«Asymptomatic natalizumab-PML cases»are associated with a bet-
ter survival and functional outcome, further justifying an early
detection thanks to the MRI follow-up (12). Once a possible PML
case is suspected, the definite diagnosis of PML requires either the
detection of JCV DNA in cerebrospinal fluid (CSF) by polymerase
chain reaction (PCR) amplification or a brain biopsy to detect JCV
DNA on histological examination. Despite improved sensitivity of
the newest quantitative PCR techniques for JCV detection in the
CSF (13), the result is frequently negative, thus, justifying repeated
CSF analysis and the use of ultra-sensitive methods that enable
the detection of a very small number of copies with a detection
limit up to 10 copies JCV DNA/ml (2, 7). Recently, the determina-
tion of CSF anti-JCV antibody index has been proposed as a new
immunological marker for early PML detection, which could be
an added tool especially in case of low JCV DNA level frequently
associated with a “false-negative” PCR for JCV DNA in the CSF
(14). The onset of PML in MS has serious prognostic implications,
as it leads to death in about 20% of patients or to serious disability
in 40% of survivors (15).
In this context of a rare unpredictable and potentially lethal
side effect of NTZ, which is usually diagnosed late and for which
there is no specific effective curative therapy, great efforts have
been directed toward the identification of markers for PML sus-
ceptibility among patients treated for MS. The search for markers
has mainly relied on the understanding of JCV-induced immuno-
logical reactions in infected NTZ recipients, as well as the specific
interactions of NTZ with immune cell trafficking.
PHYSIOPATHOLOGY OF JCV INFECTION AND REACTIVATION
TOWARD PML
JC virus infects glial cells, in particular, oligodendrocytes, lytically
(2). JCV consists of a closed, circular, double stranded DNA of
5130 nucleotides with three distinct domains: the early and late
coding regions, both controlled by a non-coding control region
(NCCR) (2). The early region is responsible for the expression of a
series of proteins, called small and large T antigens, which possess
regulatory functions in the viral replication cycle (16). The late
region encodes three classes of structural proteins VP1, VP2, and
VP3, which form the capsid of the virus, and agnoprotein (protein
necessary for DNA repair and cell cycle progression) (16).
How this virus infects cells remains partly unknown but it has
been suggested that it could use the capsid protein VP1 to enter
susceptible cells through binding to N -glycoproteins with α2,6-
linked sialic acid residues, and to 5-hydroxytryptamine (5-HT)
2A receptors (2). Following cell entry, JCV reach the nucleus via
binding to nuclear pore complexes (2).
Primary infection by JCV typically occurs in childhood and
is thought to occur in tonsillar tissue after inhalation. JCV-
infected tonsillar lymphocytes subsequently carry virions to the
kidney and bone marrow considered as the primary sites of viral
latency (2). Primary infection by JCV induces both a humoral
and a cellular adaptive immune response in the host. While the
appearance and maintenance of specific antibodies against the
virus, mainly directed against the capsid antigens, will subse-
quently attest to the primo-infection, they will not confer pro-
tective immunity against further JCV reactivation or new infec-
tion. In contrasts with the cellular immune response, which is
thought to protect the host from JCV reactivation and dissemi-
nation, and therefore, prevents PML among immunocompetent
subjects. Whereas the immune mechanisms involved in JCV qui-
escence among immunocompetent hosts are not fully under-
stood, it has been proposed that the protective cellular response
mainly relies on the generation of JCV-specific CD8 memory
cells, including long-lived effector memory CD8 cells that will
ultimately reside within the target organs. However, it has been
also shown that CD4 helper T-cells were essential for the opti-
mal generation and maintenance of the pool of memory CD8
T-cells and for optimal antigen reactivation (17, 18). Therefore,
in the absence of functional CD4 cells, unhelped CD8 JCV-
specific effector cells could fail to prevent JCV replication and
dissemination, resulting in the possibility of PML, as often occurs
in AIDS (19).
JC virus has the potential to reside and replicate in the kid-
ney, resulting in transient excretion of JCV in the urine in more
than one-third of infected subjects. Whether this kidney-specific
immune tolerance involves specific Treg populations is still a
matter of investigation.
Besides, the kidney, there are still debate concerning the poten-
tial role of CD34+ hematopoietic progenitor cells as a reservoir
and a carrier for JCV (20). Some authors also reported that JCV
could latently infect oligodendrocytes and astrocytes of healthy
individuals who do not have PML, suggesting that the brain could
also be another site of latency (21, 22).
It is important to note that the latent JCV detected in the urine,
named the archetype virus, is always genetically distinct from the
JCV detected in the brain and CSF of PML patients, which are
neurovirulent JCV mutants (23).
The rearrangement and/or formation of tandem repeats in the
NCCR of the JCV genome are certainly required for the patho-
logical infection of glial cells (24). Indeed, the mutations detected
in the brain or CSF of PML patients are always genetic rearrange-
ments, such as deletions or duplications, within the NCCR that
occur in 100% of cases (23, 25, 26). Mutations in the VP1 struc-
tural protein have also been identified in 81% of PML cases (25).
Even in PML subjects, the urinary virus usually remains arche-
typal, and mutations in the NCCR have been observed without
VP1 mutations but never the opposite, suggesting that a sequential
appearance of intrasomatic JCV mutations (25). These mutations
are considered as a necessary condition for the neurovirulence of
JCV, but the mechanisms involved in this neurovirulence remain
hypothetical: they could contribute to the immune tolerance, pro-
vide a kinetic advantage for entering into the CNS, or a selective
advantage for CNS replication.
HOW NATALIZUMAB COULD AFFECT THE IMMUNE
SURVEILLANCE AGAINST JCV
Natalizumab is a recombinant humanized monoclonal IgG4
antibody that selectively binds to the alpha chain of α4β1
and α4β7 integrin, which are expressed at the cell surface of
several hematopoietic cells (i.e., lymphocytes, monocytes, and
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eosinophils). It prevents the adhesion of cells expressing α4β1 or
α4β7 integrins, including activated T-lymphocytes, to endothelial
cells expressing vascular cell adhesion molecule-1 (VCAM-1). It
thus inhibits diapedesis through the blood–brain barrier (BBB).
The overall result is not only an organ-specific deficit in immune
surveillance, which is the basis of the therapeutic efficacy, but also
underlies the susceptibility to PML.
Several lines of evidence have recently suggested that NTZ could
exert differential effects on lymphocyte subsets. This heterogeneity
might in theory contribute to individual PML susceptibility. In
the peripheral blood, the proportion of CD4+ and CD8+ T-
lymphocytes under NTZ treatment varies among studies. Some
show a stable rate (27, 28) or a non-significant decrease (29),
others report an increased percentage of T-cells (1.3 times) (30),
but without changing the CD4/CD8 ratio (30) contrasting with
the decrease in the CD4/CD8 ratio reported in the CNS (31).
In the CSF, CD4+, and CD8+ T-cells, as well as CD19+ B-cell
and CD138+ plasma cells were found lower in NTZ-treated
patients compared with untreated MS patients or healthy sub-
jects, this lower rate persisting 6 months after NTZ cessation, but
returning to normal levels 14 months after NTZ cessation inde-
pendently of any clinical or radiological rebound phenomenon
(29, 32).
A pronounced and long-lasting decrease in CD49d (α4) expres-
sion by circulating T-lymphocytes is induced by NTZ, contrasting
with a less pronounced decrease in CD29 (β1) (27, 33). When
blood and CSF counts have been assessed in parallel, a lack of
CD49d expressing cells was observed in the CSF as expected.
However, an increased expression by peripheral T-cells of the
selectin PSGL-A, which is involved in the rolling of T-cells, was
also discovered. This increased expression could facilitate entry
into the CNS of lymphocyte subsets that are not exclusively
dependent upon the VLA4–VCAM1 interaction via the choroid
plexus. This could finally result in the maintained entrance of
MCAM-positive lymphocyte subsets such as Th17 cells, which
have been identified in the CSF of NTZ-treated patients (33).
Whether the differential impact of NTZ on T-cell subset traf-
ficking could be involved in PML susceptibility remains purely
speculative.
Despite the profound impact of NTZ on T-cells, its action can-
not be simply reduced to inhibition of the passage of activated
T-lymphocytes through the BBB. Indeed, it seems to have a broader
immunological action on various players of the innate and adap-
tive immune system such as antigen presenting cells (APC) and
natural killer (NK) cells.
In order to be presented to T-cells, the antigen must be picked
up by APC such as dendritic cells (DCs), B lymphocytes, and
macrophages. NTZ appears to have an effect on two of them, B
lymphocytes and DC. The number of CD209+ cells was found
to be decreased in the cerebral perivascular spaces of NTZ-
treated subjects as was the expression of MHC class II molecules
(expressed on the surface of DC) (34). The decreased expression of
VLA4 on myeloid DCs (mDCs) and to a lesser extent on peripheral
blood plasmacytoid DC (pDC) was reported in patients on NTZ
(35). In vitro, NTZ decreased the functional capacity of pDCs to
stimulate CD4+ T-cells (35), thus, to CD8+ T-cells. These results
suggested that in vivo, NTZ may modulate the ability of DC to
induce a CD4+ T-cell-specific response (35) with a subsequent
deficient anti-JCV response.
CNS resident DC are indeed key players in the immune
defense against JCV: following priming by CNS replication, tissue
imprinted DC migrate toward the draining lymph nodes where
they contribute to the activation of T-cell populations, including
naive T-cells, central memory cells, and effector T-cells, all of which
will recirculate toward the CNS and support the anti-JCV effector
function of the long-term CNS resident pool of memory effector
cells (36). Along the same lines, interesting results on MHC class
II molecules have been recently emphasized. The HLA-DR1*15
haplotype, which is also the most strongly associated genetic risk
factor of MS, has been linked with a protective effect against JCV
infection, whereas a strong negative association was reported for
the HLA DQB1*06:03 haplotype (37, 38). Genetic characteriza-
tion of the HLA complex could therefore help to determine an
individual’s risk of PML.
Natalizumab exerts some effects on B-cells: (i) it mobilizes
CD34+ progenitor cells out of bone marrow into peripheral blood
and elevates persistently circulating CD19+ B-cells, particularly
CD19+ CD10+ pre-B-cells for extended periods (20, 39); (ii) it
leads to a global increase in the proportion of CD 20+ B-cells
whereas the percentage of B-cells expressing VLA4 is reduced (27);
and (iii) it modifies B subpopulations with a decrease in naive B-
cells and an increase in memory B-cells (CD19+CD27+IgD−)
(30). As memory B-cells need the VLA-4/VCAM-1 interaction to
be contained within the spleen, blocking this interaction could
lead to the release of memory B-cells from the spleen.
Though still a matter of debate, it has been highlighted that
B-cells and CD34+ progenitors could play a role in the patho-
physiology of PML, as these cells might be a reservoir of JCV (20,
39–41). The release of pre-B-cells and CD34+ stem cells from the
bone marrow to the periphery could be one of the mechanisms
behind an increase in JC viremia, thus, promoting the emergence
of PML (42). Since 1992, special attention was paid to the capac-
ity of CD34+ to be infected by JCV, allowing the transfer of JCV
into lymphocytes (40, 43). This hypothesis has been reinforced by
recent in vivo findings, emphasizing the detection of a higher JCV
DNA load in CD34+ cells and in CD19+ cells among NTZ-treated
patients, suggesting that subclinical JCV reactivation may occur in
blood. Whether the detection of cellular JCV DNA could be used
for risk stratification algorithms remains to be explored (39, 41).
Nevertheless, the JCV DNA load detected was very low in these
patients and JCV DNA copies have also been identified in healthy
subjects and in MS patients during interferon therapy, impacting
the specificity of such findings (44).
B-cells may also play a role in the transport of JCV within
the CNS. Indeed, the infection of pre-B-cells by the JCV arche-
type (form of the virus during primary infection) might allow
changes in the regulatory region during the development and mat-
uration of B-cells, in particular, via the expression of RAG 1 and
RAG 2 recombinases [needed for somatic recombination of V (D)
J rearrangement of immunoglobulin] and the AID (activation-
induced cytidine deaminase) enzyme, which allows somatic hyper-
mutation, gene conversion, and immunoglobulin class switching
(45). Therefore, the genesis of B-cells and antibodies could alter
the genotype of JCV and allow it to be expressed within B-cells
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and glial cells (45). Finally, assuming that DRB1*06:03 seems to
have a positive association with anti-JCV antibody status, one can
speculate that less effective viral control can lead to a chronic
higher stimulation of B-cells and an increase in anti-JCV antibody
levels (38).
JCV-SPECIFIC ANTIBODIES AND PML PREDICTION
Estimating the individual risk of PML remains a major challenge,
and therapeutic use of NTZ in MS is guided by the overall esti-
mation of the probability of developing PML. Since the approval
of NTZ, three main risk factors for PML have been identified
and are generally used in a clinical setting: the presence of JCV-
specific antibodies, the increasing duration of treatment (with a
peak at 24 months), and a history of immunosuppressive therapy.
Combining the three risk factors result in a PML probability of
1:91 (46), which largely exceeds the overall probability of 3/1000.
However, these risk factors are far from satisfactory to achieve a
reliable individual prediction of PML, a goal that remains a crucial
challenge for clinicians.
The absolute prerequisite for PML development is previous
contact with JCV, which can be confirmed retrospectively by the
presence of JCV-specific antibodies (47) (Figure 1). Hence, a two-
step serological assay consisting of an enzyme-linked immunosor-
bent assay (ELISA) was developed a few years ago. This assay is
based on the detection of antibodies against JC virus-like parti-
cles (VLPs). In 2013, this technique was expanded to a second-
generation JCV antibody ELISA, which provides better sensitivity
and specificity (48) by pre-coating the JC VLPs on microtiter
plates (48). In this second assay, reproducibility has been improved
thanks to a ready-to-use kit, and the cross-reactivity of BK virus-
specific antibodies appeared to be very low. The proportion of
false negatives is low at around 2.5% (49). On the whole, 50–60%
of multiple sclerosis patients are positive for JCV antibodies (48,
50, 51) but only a very small proportion will develop PML, illus-
trating that stratification according to JCV antibodies does not yet
allow a precise individual prediction of PML. Interestingly, JCV
IgG seroprevalence increases with age (up to 68% of people by the
age of 59) (24). Depending on the studies and the serological test
used, approximately 50–90% of adults have been exposed to JCV
whereas 19–27% of these shed JCV in their urine (2).
Anti-JCV antibody levels have been proposed to improve the
prediction of PML in NTZ-treated patients. An increase in serum
anti-JCV antibody levels was observed at the onset of PML, and
interpreted as being related to a new site of lytic infection, and/or
to the pathogenic transformation of the virus (52).
Starting out from this observation, a quantitative anti-JCV anti-
body index is currently being investigated to determine its putative
predictive value, with the hypothesis that increasing titers could
reflect an increasing risk (53) (Figure 1). One point worth men-
tioning is that the anti-JCV antibody index does not correlate
with duration of exposure to NTZ (53). A major restriction that
emerged from the first studies was that the kinetics of JCV anti-
bodies could not be predictive among patients with prior use of
immunosuppressive drugs, who are those with the highest PML
risk: indeed, there was no difference between PML and non-PML
patients for the distribution of the anti-JCV antibody index in this
subpopulation (53).
Among patients without prior immunosuppressant use, a link
between a higher anti-JCV antibody index and a greater risk
of PML was suggested (53) and a cut-off point of 1.5 for the
antibody index was proposed to identify patients with a higher
risk. More precisely, among patients without prior immunosup-
pressant use and with an anti-JCV antibody index at or below
thresholds of 0.9–1.5, the risk of PML remained low during the
first 2 years of treatment (approximately 0.1/1000 patients, i.e.,
the same as anti-JCV antibody-negative patients), and extended
from 0.3/1000 (if index below 0.9) to 1.3/1000 (if index between
0.0 and 1.5) after 25 months of treatment. Importantly, the cut-
off of 1.5 seems to be the value “not to be exceed.” Above that
threshold, the risk of developing PML was estimated to be 1/1000
patients during the first 2 years of treatment and ranged from
8.1 to 8.5/1000 after 25 infusions. These recent results could
have a significant impact for the management of NTZ-treated
patients. Having an anti-JCV antibody index <0.9 corresponds
to a very low risk of PML, which could allow considering ther-
apy maintenance despite seropositivity. On the contrary, having
FIGURE 1 | Immunological markers to estimate individual PML risk in NTZ-treated patients.
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an anti-JCV antibody index >1.5 could be interpretated as a «red
flag», encouraging reconsidering the risk-benefit balance and to
increase clinical and MRI surveillance if therapy is pursued. Finally,
an index between 0.9 and 1.5 might be considered as a «gray area»in
which PML risk can increase with time (up to 1.3/1000 patients),
which requires to discuss continuation of therapy at the individual
level. Briefly, the lower anti-JCV antibody index, the higher safety
seems to be.
However, to date, this quantitative approach has still to be fur-
ther validated and is not yet recommended for general use, and
clinical decisions are still mainly based on the positive or negative
serological status.
Initial interpretations of this serological test suggested that a
negative status could be used to reassure patients as the proba-
bility of developing PML is very low at <1/10000. A longitudinal
serological follow-up from the combined AFFIRM and STRATIFY-
1 studies showed, however, that only 87% of patients who were
anti-JCV antibody negative at baseline remained consistently neg-
ative every 6 months over a period of 18 months (53) meaning
that nearly 13% could become positive during follow-up. Interest-
ingly, 39% of them reverted back to negative at least once during
the 18 months whereas 69 and 74% remained below the anti-JCV
antibody index threshold of 0.9 and 1.5, respectively (53). This was
interpreted as relating either to an initial false negative, serocon-
version during follow-up or low levels of antibodies, which could
fluctuate slightly around the positivity cut-off. Therefore, negative
JCV serology at treatment initiation is not sufficient for long-term
reassurance and the current recommendation is to test patients
every 6 months for antibody levels (54).
NEW APPROACH BASED ON LEUKOCYTE CELL MEMBRANE
MARKERS
Several immunological biomarkers related to cell surface mole-
cules, mainly those belonging to the integrin and selectin fami-
lies and involved in cell trafficking through the BBB, have been
investigated for their predictive value (Figure 1).
Several modifications in integrin expression have been pointed
out following NTZ initiation. Down-regulation of CD49d and
CD29 (subunit of VLA-4) expression on both CD4+ and CD8+
T-cells has been shown in patients treated with NTZ, as early
as the first months of therapy and lasting several years (55).
The decreased expression of CD11a (the α chain of lymphocyte
function-associated antigen 1 or LFA-1) on both CD4+ and CD8+
T-cells was detected at 24 months, which corresponds to the peak
incidence of PML (55). To a lesser extent, a decrease in CXCR3
was also observed after 1 year. Assuming that VLA-4 and LFA-1
are crucial for the migration of Th1 and Th17 lymphocytes into
the central nervous system (56), their decreased function could
be involved in the inhibition of anti-JCV-specific T-cell trafficking
in the CNS, thus, leading to PML (57). However, these mark-
ers have not yet demonstrated their predictive value in a clinical
setting.
The role of L-selectin, named CD62L, a cell adhesion mole-
cule expressed on T-lymphocytes, has recently been highlighted.
L-selectin plays a crucial role in the initial step of the adhesion cas-
cade, the capture of leukocytes from the blood and the rolling along
the vascular endothelium (58). Moreover, getting rid of L-selectin
from activated T-cells prevents their reentry into peripheral lymph
nodes, which could have an impact on T helpers.
A recent study demonstrated that the proportion of CD4+ T-
cells expressing L-selectin was lower in long-term NTZ-treated
patients than in untreated MS patients or healthy controls, and
an unusually low percentage of CD4+ T-cells expressing CD62L
was associated with a higher risk of developing PML (59). In
NTZ-treated patients who developed PML, a dramatic decrease
in CD62L+ cells has been described prior to PML onset in a
small number of cases (59). No correlation seems to be observed
between CD62L-expressing-cells and JCV seropositivity or prior
use of immunosuppressive drugs (59). One limitation of this study
is due to the fact that the PBMC were cryopreserved, which could
have severely modified cell expression of selectins. Therefore, a
confirmatory study on fresh cells is awaited. To explain the possible
link between the decrease in CD62L and PML, several hypotheses
have been put forward. As CD62L is involved in T-cell trafficking
though the BBB, it could contribute to preventing the entrance
of anti-JCV T-cells into the CNS. CD62L is also involved in the
final function of T effector cells in the CNS, thus, in mediating
demyelinating damage (60). Therefore, the lack of CD62L could
have a negative impact on the capacity of JCV-specific T-cells to kill
infected oligodendrocytes. Finally, CD62L expression is crucial for
lymphocyte migration toward lymph nodes (61), and decreased
expression could also impair the activation of naive T-cells by APC
in lymph nodes (59). Consequently, NTZ seems to decrease not
only T-cell trafficking but also their activation by APC at the same
time, thus, leading to impairment of immune defenses against viral
infection, especially JCV infection.
While these results are awaiting confirmation in prospective
studies, it has been proposed that the bi-yearly monitoring of
CD62L expression on D4+ T-cells after 18 months of NTZ treat-
ment could help to evaluate the individual risk of PML (59).
Whether the combined monitoring of L-selectin, CD49d, and
CD11a could predict the individual risk of PML among NTZ-
treated patients is an important question to be answered in future
studies.
DYNAMICS OF PERIPHERAL JCV EFFECTOR MEMORY
T-CELLS AS A MARKER OF JCV REACTIVATION
The detection of circulating JCV-specific activated effector mem-
ory T-cells (TEM) has been proposed to improve the identification
of patients with a high risk of PML (62) (Figure 1). One underly-
ing idea was that following reactivation of the JCV and production
of JCV antigens, which could occur in the brain, APC will migrate
toward the draining lymph nodes and promote the activation of
anti-JC T-lymphocytes, including effector memory T-cells. Once
these effector cells are activated they migrate into the peripheral
circulation where they will remain, as their entrance in the CNS
is inhibited by NTZ. They can therefore be detected thanks to
their release of INF-γ, which can be examined by an enzyme-
linked immunosorbent spot assay (ELISPOT). In 2009, Chen and
colleagues first tried to determine JCV protein VP1-specific T-
cell responses thanks to an interferon gamma immunospot assay
(63). PBMCs were isolated from patients treated for more than
18 months and were exposed to four pools of overlapping peptides
to cover the entire JCV protein VP1. A decrease in spot-forming
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units (SFU) was observed between 6 and 12 months for three pep-
tide pools, suggesting that NTZ could have a negative effect on the
virus-specific T-cell response (63).
Recently, a new test for the detection of JCV-specific effec-
tor memory T-cells (TEM) using an ELISPOT procedure has
been developed and assessed among NTZ-treated patients (62).
A threshold for positivity had been defined from healthy sub-
jects, and the initial assessment of this ELISPOT test on a patient
with a biopsy proven PML but negative JCV PCR in the CSF
showed a strong positivity for circulating TCM, suggesting that
the presence of detectable JCV-specific TEM accompanied the
onset of PML. Screening for JCV-specific TEM responses in “non-
PML subjects,” belonging to three groups (RR-MS under NTZ,
untreated RR-MS, and healthy donors) showed that the frequency
of JCV TEM responses increased with the time on NTZ, with
a peak at 24 months, meaning that prolonged NTZ treatment is
sometimes associated with JCV reactivation. In addition, most of
the patients who developed PML showed high titers. TEM pos-
itivity was detected almost exclusively in patients with positive
serology for JCV, but identified only a minority of seropositive
subjects (16.1%) (62). Therefore, the detection of JCV-specific
TEM using this ELISPOT procedure could help to identify the
minority of patients with positive JC serology whose JCV could
reactivate. This opens up a promising perspective to improve the
identification of patients with a higher PML risk, thus, justifying
the setting up of larger longitudinal trials among NTZ-treated MS
patients.
The cellular production of other cytokines by T-cells, either
from the blood or CSF, has been investigated in several studies
among patients with NTZ-related PML. Blood T-cell responses
were dominated by IL-10 production rather than IFN-γ produc-
tion, and higher levels of IL-10, IL-5, and IL-15 were detected in
the CSF shortly after the diagnosis of PML (64). Starting from the
premise that IL-10 production is associated with poor control of
viral infections, NTZ-associated PML could be marked by a switch
of cytokine production from Th1 to Th2. Given that early false-
negative detection of JCV DNA in the CSF by PCR can occur,
measuring IL-10, IL-5, and IL-15 in the CSF may help to diag-
nose PML. Nevertheless, intra cellular cytokine assay seems to be
difficult to use in routine analysis.
NATALIZUMAB AND THE T-CELL RECEPTOR REPERTOIRE
The T-cell receptor (TCR) repertoire is diverse thanks to the com-
binatorial rearrangement of TCR genes and their recombination
during these rearrangements. Rearrangement of V, D, and J gene
segments encodes for CDR3, which is involved in TCR contact with
peptide-CMH complex (65). In MS patients, the T-cell repertoire
is altered compared to healthy patients (66) with a sharp increase in
the frequency of TCR β chain variable region (TCRβV) expansions
in the peripheral blood over time (67). NTZ was shown to curb
expansion of the TCR repertoire in blood, with a lower propor-
tion of Vbeta elements with TCR repertoire expansions in blood
(68). In addition, TCR repertoire alterations in CSF were more
pronounced in NTZ-treated than in untreated patients (68). As
TCR repertoire diversity plays a role in antiviral immunity (65),
NTZ may weaken such antiviral defenses. Interestingly, additional
peripheral TCR expansions have been identified 3 months after
diagnosis of NTZ-related PML that preceded the development of
an immune reconstitution syndrome (IRIS): whether this reflects
the recovery of efficient antigen recognition should be investigated
further. Overall, though potentially promising, these results should
be reproduced. For the moment, however, they are far from being
exploitable in routine clinical practice.
microRNAs AND INDIVIDUAL PML RISK ASSESSMENT
Epigenetic mechanisms, such as microRNAs (miRNAs) changes,
have recently been shown to be involved in MS pathophysiology
(69). microRNAs are a class of small, highly conserved, non-coding
RNA molecules that control gene expression by binding to comple-
mentary sequences in the 3′ untranslated regions of the messenger
RNAs (70). They play an important role not only in modulat-
ing innate immunity, especially antiviral immunity, but also in
adaptive immunity by regulating B- and T-cell development and
differentiation (71). The study of B-cells in NTZ-treated patients
highlighted that it could modulate the expression of a particu-
lar set of deregulated miRNAs found in untreated MS patients
(72). Within the first 6 months of treatment, a decrease in let-
7c, miR-125a-5p, and an increase in miR-642 expression have
been found (73). Interestingly, miR-125a-5p could play a role in
the leukocyte migration process and in the regulation of brain
endothelial integrity. Furthermore, it has been suggested that three
other miRNAs, miR-320, miR-320b, and miR-629, are related to
PML: miR-320 and miR-320b showed higher expression and miR-
629 lower expression in PML patients than in non-PML patients
(73). Remarkably, it has been suggested that miR-320b may have
“virus–host interaction,” thus, its higher expression in anti-JCV
antibody-positive patients pave the way for its putative relation-
ship with the virus and PML (73). Although miRNAs have been
linked to B virus chronic infection, the possible role of miRNAs
in viral infection remains to be confirmed. Finally, miR-320 and
miR-320b have binding sites in L-selectin, another possible bio-
marker of PML. Whether this indicates a direct link between the
two markers, miR-320 and miR-320b impacting the interaction
between L-selectin and the endothelial cells, remains to be assessed.
Another micro RNA, miRNA-126, has been associated with PML
(74), and could point to a relevant pathophysiological interaction
with PML onset by acting on JCV replication: Mir-126 blockade
was found to increase POU2AF1 (75) a crucial regulator of the
transcription factor Spi-B (76), which is involved in early JCV
gene expression and JCV activity (77).
Overall, whether these miRNAs will finally serve as biomarkers
for the early detection of PML in NTZ-treated patients in the future
remains to be assessed in a longitudinal clinical setting (Figure 1).
PERSPECTIVES AND CONCLUSION
Despite potential life-threatening side effects such as PML, NTZ
is one of the most effective therapies for RR-MS. Estimating an
individual’s risk of PML is still a major challenge, and therapeu-
tic strategies are mainly guided by an overall estimation of PML
probability. Up to now, monitoring is currently based on clinical
data (NTZ exposure and prior use of immunosuppressive drugs),
MRI scanning and presence of JCV-specific antibodies. Adding the
anti-JCV antibody index in patients without prior use of immuno-
suppressive drugs to better determine PML risk is now a promising
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alternative. Although this marker needs to be further validated, a
high anti-JCV antibodies index (>1.5) encourages extreme cau-
tion, and if treatment is maintained, justifies a narrow clinical and
MRI follow-up. In case of PML suspicion, NTZ should be immedi-
ately stopped and CSF analyzed for JCV DNA screening and even-
tually determination of CSF JCV antibody index. Interestingly, sev-
eral novel immunological biomarkers that could help to identify
patients with a high risk of PML more accurately have been iden-
tified. These include selectin-positive circulating T-lymphocytes,
JCV effector memory T-cells, or miRNA levels (Figure 1). The
real predictive value of these markers still needs to be investigated
in clinical trials. Though it is not yet possible to accurately pre-
dict the risk of PML in individual patients, these new markers have
paved the way for «new combined monitoring», which will include
immunological screening, in NTZ-treated patients.
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